During the corresponding time, Royalty Pharma Plc recorded a revenue increase by 16.5 % year on year, sequentially revenue grew by 6.91 %. While revenue at the Royalty Pharma Plc's corporate clients
: This article discusses the recent announcement by Royalty Pharma plc regarding its acquisition of a synthetic royalty on U.S. sales of Geron Corporation s RYTELO for $125 million. The financial implications of this acquisition are explored in the context of Royalty Pharma s overall performance in the second quarter of 2024, highlighting its return on investment (ROI) figures relative to the healthcare sector. In a significant strategic move, Royalty Pharma plc (Nasdaq: RPRX) has announced its intentions to acquire a synthetic royalty on the U.S. sales of Geron Corporation s (Nasdaq: GERN) therapeutic agent RYTELO for an upfront payment of $125 million. This acquisition underscores Royalty Pharma s aggre...
In a major strategic move, Royalty Pharma plc (Nasdaq: RPRX) has recently sealed an agreement to acquire Agios Pharmaceuticals royalty on Servier s revolutionary drug, vorasidenib. The deal, worth an impressive $905 million in upfront cash, is contingent upon the approval of vorasidenib by the U.S. Food and Drug Administration (FDA). This acquisition marks yet another milestone for Royalty Pharma, as it strives to expand its portfolio and solidify its position within the pharmaceutical royalty industry.The collaboration between Royalty Pharma and Agios Pharmaceuticals brings together two leading enterprises, each contributing their unique strengths to drive innovation and fuel significant breakthroughs in p...
Royalty Pharma and Cytokinetics Secure Strategic Funding Collaboration to Propel Commercial Launch of Aficamten and Drive Advancements in Cardiovascular ResearchIn a major development that holds great promise for the pharmaceutical industry, Royalty Pharma plc and Cytokinetics, Incorporated have joined forces in an expanded strategic funding collaboration. Both companies are poised to benefit from this collaboration, as it provides the necessary capital to support the commercialization of aficamten, a groundbreaking drug, and further advances Cytokinetics cardiovascular pipeline. This collaboration not only accelerates advancements in muscle biology-focused specialty cardiology but also diversifies access t...
Sources:
Royalty Pharma Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Royalty Pharma Plc’s corporate clients.
For your research, we’ve provided 9 tables on Royalty Pharma Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
182.9 %